Table A1.
Median proportion of three types of monocytes in patients with COVID-19, convalescent patients with COVID-19 and healthy controls (HC). Data expressed as median (Q1–Q3). (* p < 0.05 in Kruskal–Wallis ANOVA test and post-hoc analysis).
| Patients with COVID-19 a Median (Q1–Q3) |
Convalescent b Median (Q1–Q3) |
Control Group c Median (Q1–Q3) |
p < 0.05 * Group A-B-C ANOVA, Kruskal–Wallis |
p < 0.05 * between Groups Post-Hoc |
|
|---|---|---|---|---|---|
| All monocytes [%] | 5.5 (3.8–7.6) | 7.0 (4.6–9.1) | 6.4 (4.4–7.5) | p = 0.1038 | - |
| All monocytes [k/ul] | 376 (260–453) | 535 (399–815) | 356 (287–437) | * p < 0.0001 | * a–b, b–c |
|
Classical monocytes CD14++ CD16− |
83.2 (76.5–87.1) | 84.2 (76.9–88.8) | 67.3 (60.7–70.9) | * p < 0.0001 | * a–c, b–c |
|
Intermediate monocytes CD14+ CD16+ |
7.5 (4.4–15.7) | 7.7 (5.6–11.7) | 5.2 (3.9–7.2) | * p = 0.0472 | - |
|
Non-classical monocytes CD14−/+ CD16++ |
0.9 (0.3–1.8) | 2.2 (1.1–4.3) | 14.9 (12.5–16.8) | * p < 0.0001 | * a–b, a–c, b–c |